MX2018013520A - Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control. - Google Patents

Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control.

Info

Publication number
MX2018013520A
MX2018013520A MX2018013520A MX2018013520A MX2018013520A MX 2018013520 A MX2018013520 A MX 2018013520A MX 2018013520 A MX2018013520 A MX 2018013520A MX 2018013520 A MX2018013520 A MX 2018013520A MX 2018013520 A MX2018013520 A MX 2018013520A
Authority
MX
Mexico
Prior art keywords
monoclonal antibodies
antibodies targeting
checkpoint molecules
dna monoclonal
targeting checkpoint
Prior art date
Application number
MX2018013520A
Other languages
English (en)
Inventor
Muthumani Karuppiah
Weiner David
Sardesai Niranjan
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2018013520A publication Critical patent/MX2018013520A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

En la presente se divulga una composición que incluye una secuencia de ácido nucleico recombinante que codifica un anticuerpo o un fragmento del mismo que se dirige a una molécula reguladora inmunitaria; la divulgación también proporciona un método para prevenir y/o tratar una enfermedad en un sujeto mediante el uso de dicha composición y método de producción.
MX2018013520A 2016-05-05 2017-05-05 Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control. MX2018013520A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332386P 2016-05-05 2016-05-05
PCT/US2017/031440 WO2017193094A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting checkpoint molecules

Publications (1)

Publication Number Publication Date
MX2018013520A true MX2018013520A (es) 2019-06-10

Family

ID=60203434

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013520A MX2018013520A (es) 2016-05-05 2017-05-05 Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control.

Country Status (12)

Country Link
US (1) US11896654B2 (es)
EP (1) EP3452107A4 (es)
JP (2) JP7280821B2 (es)
KR (1) KR102375327B1 (es)
CN (1) CN109789225A (es)
AU (1) AU2017261367B2 (es)
BR (1) BR112018072723A2 (es)
CA (1) CA3023118A1 (es)
EA (1) EA201892522A1 (es)
MX (1) MX2018013520A (es)
SG (2) SG11201809789SA (es)
WO (1) WO2017193094A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
CN117586403A (zh) 2016-10-11 2024-02-23 艾吉纳斯公司 抗lag-3抗体及其使用方法
EP3609921A2 (en) 2017-04-13 2020-02-19 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
WO2018222949A1 (en) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
CA3078458A1 (en) * 2017-10-06 2019-04-11 The Wistar Institute Of Anatomy And Biology Dna monoclonal antibodies targeting ctla-4 for the treatment and prevention of cancer
WO2019152602A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Structurally modified flavivirus dmabs
MX2021008387A (es) * 2019-01-11 2021-10-13 Wistar Inst Anticuerpos monoclonales de and dirigidos a pd-1 para el tratamiento y prevención de cáncer.
US20200283796A1 (en) * 2019-03-05 2020-09-10 Massachusetts Institute Of Technology Dna launched rna replicon system (drep) and uses thereof
CN112007149A (zh) * 2019-05-29 2020-12-01 思格(苏州)生物科技有限公司 一种新型复合免疫佐剂及其应用
WO2021226343A1 (en) * 2020-05-07 2021-11-11 The Wistar Institute Of Anatomy Andbiology Dna antibody constructs for use against hepatitis b virus
WO2023064841A1 (en) * 2021-10-13 2023-04-20 The Wistar Institute Of Anatomy And Biology Antibodies for use against sars-cov-2
CN116444656B (zh) * 2022-01-10 2023-09-22 东莞市朋志生物科技有限公司 一种鉴别新冠突变型抗原的抗体、试剂及方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2970873C (en) * 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
AU2006327514B2 (en) * 2005-12-19 2010-04-15 Dabur Pharma Limited DNA vaccine for cancer therapy
AU2009296392B2 (en) * 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
KR20210088741A (ko) 2012-12-13 2021-07-14 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｄｎａ 항체 작제물 및 그 이용 방법
US9687823B2 (en) * 2012-12-14 2017-06-27 Chevron U.S.A. Inc. Hydroprocessing co-catalyst compositions and methods of introduction thereof into hydroprocessing units
EP3080159A4 (en) 2013-12-13 2017-08-02 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies

Also Published As

Publication number Publication date
KR20190033047A (ko) 2019-03-28
EP3452107A4 (en) 2020-04-15
US20190142920A1 (en) 2019-05-16
AU2017261367B2 (en) 2024-04-04
JP2019515044A (ja) 2019-06-06
AU2017261367A1 (en) 2019-01-03
EP3452107A1 (en) 2019-03-13
CA3023118A1 (en) 2017-11-09
CN109789225A (zh) 2019-05-21
JP7280821B2 (ja) 2023-05-24
US11896654B2 (en) 2024-02-13
BR112018072723A2 (pt) 2019-02-19
SG10202011027QA (en) 2020-12-30
EA201892522A1 (ru) 2019-05-31
WO2017193094A1 (en) 2017-11-09
KR102375327B1 (ko) 2022-03-17
JP2023033329A (ja) 2023-03-10
WO2017193094A8 (en) 2018-06-07
SG11201809789SA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
MX2018013520A (es) Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control.
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
CL2017001328A1 (es) Anticuerpos heterodimericos que unen cd3 y antígenos tumorales
PE20150023A1 (es) Proteinas de union a antigeno st2
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
BR112017011326A2 (pt) anticorpo, ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo, imunoconjugado, composição farmacêutica, usos do anticorpo, métodos para tratar ou retardar a progressão de distúrbio proliferativo celular e para intensificar a função imune
BR112017006203A2 (pt) anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune.
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112017020915A2 (pt) ?anticorpo de mamífero isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo caninizado ou fragmento de ligação ao antígeno caninizado do mesmo, anticorpo monoclonal caninizado ou fragmento de ligação ao antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo isolado, proteína de fusão, composição farmacêutica, e, método para diminuir a atividade de uma célula imune?
EA201592006A1 (ru) Новые биспецифические связывающие молекулы с противоопухолевой активностью
MX2017006301A (es) Conjugados de anticuerpo- farmaco.
CL2008003784A1 (es) Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
PH12019502298A1 (en) Monoclonal antibody to pd-l1
AR118763A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
MY191894A (en) Antibodies that bind zika virus envelope protein and uses thereof
EA201790437A1 (ru) Антигенсвязывающие белки, связывающиеся с cxcr3
BR112017025036A2 (pt) peptídeo; ácido nucleico; parcela de ligação; composição farmacêutica; peptídeos e/ou ácidos nucleicos e/ou parcelas de ligação; peptídeos e/ou ácidos nucleicos e/ou parcelas de ligação para uso; e ácido nucleico para uso
MX2018013523A (es) Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.
AR111767A1 (es) Proteínas de unión al antígeno anti-jagged1